Why Was Danuglipron Discontinued? Pfizer's Walk-Away from the Oral GLP-1 Race

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited

Key Takeaways

• Pfizer discontinued the twice-daily danuglipron formulation on December 1, 2023
• The primary driver was GI adverse-event rates that produced 30-50% discontinuation in phase 2
• Competitive pressure from Lilly's more advanced orforglipron contributed to the strategic decision
• A subsequent once-daily modified-release attempt was also paused during 2024-2025
• The discontinuation removed a competitive oral GLP-1 from the U.S. obesity pipeline. FormBlends does not sell or supply danuglipron

Direct answer

Pfizer discontinued danuglipron's twice-daily formulation in December 2023 because phase 2 trials produced high rates of gastrointestinal adverse events and discontinuation. Approximately 30 to 50 percent of patients at therapeutic doses left the trials due to nausea, vomiting, or diarrhea. The decision also reflected competitive pressure: Lilly's orforglipron, a once-daily oral GLP-1, was further along with better tolerability. Pfizer briefly pursued a modified-release once-daily danuglipron formulation, then paused that program. The molecule is effectively shelved as of May 2026.

Table of contents

1. The data behind the discontinuation
2. Why twice-daily dosing caused problems
3. The orforglipron factor
4. The financial math of phase 3
5. The once-daily attempt and why it failed too
6. What this means for the oral GLP-1 landscape
7. Lessons for drug development
8. What replaced danuglipron in Pfizer's portfolio
9. The contrary view: was it salvageable?
10. FAQ
11. Sources

The data behind the discontinuation

Pfizer's December 2023 announcement was specific about the issues. The reported phase 2b data showed:

• Nausea rates of 50-70% at therapeutic doses
• Vomiting in 20-35% of patients
• Diarrhea in 25-40%
• Discontinuation due to adverse events: 30-50% at the highest doses studied
• Liver enzyme elevations in a subset of patients, monitored but not the primary issue

For context, injectable semaglutide produces nausea in ~44% of patients in phase 3 trials, with discontinuation rates around 7%. Tirzepatide produces nausea in ~31% and discontinuation ~7%. Danuglipron's GI signal was substantially worse than the leading injectables, and the discontinuation rate would have been catastrophic in a phase 3 setting where adherence drives outcomes.

Pfizer's analysis concluded that the twice-daily formulation could not be reliably improved through titration or dose adjustment alone. The drug's pharmacokinetic profile was producing the tolerability problem at the level of formulation, not patient behavior.

Why twice-daily dosing caused problems

GLP-1 receptor activation produces nausea through brainstem signaling (area postrema and related circuits). The nausea response is dose-dependent and exposure-dependent. Two factors govern how patients tolerate it:

1. Peak exposure level. Higher peaks produce more nausea
2. Tachyphylaxis. Sustained moderate exposure allows the nausea response to attenuate over time, while repeated peaks restart the cycle

Injectable once-weekly GLP-1 drugs produce a slow exposure curve with one peak per week. Patients experience nausea for a few days after each injection, then attenuation kicks in. Over a few weeks the body adapts.

Danuglipron's twice-daily oral schedule produced 14 peaks per week, each driving a fresh nausea signal. The body never had time to attenuate before the next peak arrived. This is a known formulation challenge for small-molecule drugs targeting receptors with strong acute side effects.

The theoretical fix is modified-release formulation, which smooths the curve. That's what Pfizer tried with the once-daily version, but other factors intervened.

The orforglipron factor

Lilly's orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist. By late 2023, orforglipron had:

• Phase 2 efficacy of approximately 14% weight loss at 36 weeks at the highest dose
• Phase 2 tolerability comparable to or better than injectable semaglutide
• Phase 3 trials initiated
• Strong commercial backing from Lilly's existing infrastructure

For Pfizer, the strategic implication was clear: even if danuglipron could be reformulated, it would arrive after orforglipron with weaker efficacy and worse tolerability. The competitive position was untenable.

Drug companies invest in phase 3 based on probability-weighted future revenue. A best-in-class oral GLP-1 would be a multi-billion-dollar franchise. A second-best or third-best oral GLP-1, with worse tolerability, has dramatically less commercial value.

Pfizer made the call based on portfolio economics as much as on the drug's own data.

The financial math of phase 3

An obesity phase 3 trial program runs to several hundred million dollars. Multiple trials are needed (efficacy in obesity, efficacy in diabetes, cardiovascular safety, long-term maintenance, special populations). Total phase 3 to commercial launch investment for a major obesity drug runs into the billions.

Pfizer's danuglipron investment math:

• Estimated phase 3 program cost: $1-2 billion
• Risk-adjusted probability of FDA approval: low, given the tolerability problem
• If approved, expected market share: small, given orforglipron's lead position
• Net present value: likely negative

The decision to discontinue rather than press forward was the financially rational choice. The reputational cost of the discontinuation (stock drop, analyst criticism) was lower than the cost of a failed phase 3 program.

The once-daily attempt and why it failed too

Pfizer announced after the twice-daily discontinuation that it would pursue a modified-release once-daily formulation. The theory: smoother pharmacokinetics would solve the tolerability problem while preserving the molecule's efficacy.

The once-daily program made progress through early development but was paused during 2024-2025. Reasons:

• The modified-release pharmacokinetics did produce smoother curves, but tolerability gains in early studies were modest
• Orforglipron continued to advance, further reducing the competitive opportunity
• Pfizer's strategic priorities shifted; obesity was not the company's lead therapeutic area
• Internal portfolio review weighted danuglipron lower than competing investments

The once-daily story is a smaller-scale repeat of the twice-daily story: the molecule's commercial position kept eroding as competitors advanced.

What this means for the oral GLP-1 landscape

Danuglipron's exit reduces the field of oral GLP-1 candidates approaching the market. The remaining competitive landscape:

• Orforglipron (Lilly). Phase 3 ongoing, expected to file in 2025-2026. Most likely first oral GLP-1 specifically for obesity.
• Oral semaglutide 50 mg (Novo). Phase 3 OASIS program; ~15% weight loss at 68 weeks. Filed for the obesity indication.
• Other small molecules. Multiple early-phase candidates from various companies.

For patients seeking oral GLP-1 therapy, the field is narrower than it would have been with danuglipron in it. The two leaders, orforglipron and oral semaglutide 50 mg, are both well into development.

Lessons for drug development

The danuglipron story is studied in drug development circles as an example of:

Lesson 1: Pharmacokinetics matter as much as pharmacodynamics. A drug can work at the receptor level and still fail commercially because of how it gets to the receptor.

Lesson 2: Twice-daily chronic dosing is a hard ask. Patient adherence drops with each additional dose per day. Combined with peak-driven side effects, twice-daily oral chronic therapy faces structural disadvantages.

Lesson 3: Phase 2 is the truth-teller. By the time a drug reaches phase 3, the major characteristics are locked in. Phase 2 tolerability problems generally do not resolve in phase 3.

Lesson 4: Competitive position drives discontinuation decisions. A drug can be killed by competitor data even when its own data is acceptable, if the commercial math doesn't work.

Lesson 5: Pfizer's obesity strategy lost ground. Walking away from danuglipron without a clear replacement left Pfizer behind Lilly and Novo in oral obesity.

What replaced danuglipron in Pfizer's portfolio

Pfizer's obesity strategy after danuglipron's discontinuation has been less prominent. Disclosed elements include:

• Investment in alternative obesity assets through licensing and partnerships
• Research into combination products (oral GLP-1 plus other mechanisms)
• Continued evaluation of internal early-phase candidates
• Strategic interest in acquisitions of obesity-focused biotech companies

No announced phase 3 oral obesity asset has emerged from Pfizer as of May 2026. The company's market position in obesity remains modest compared to Lilly and Novo.

The contrary view: was it salvageable?

Some industry observers argued that Pfizer walked away too quickly.

Argument 1: The receptor worked. Danuglipron produced real efficacy. Reformulation could have addressed tolerability.

Argument 2: Tolerability often improves with experience. Phase 2 GI rates in early GLP-1 trials are routinely worse than phase 3 rates with refined titration. Pfizer might have benefited from a more careful phase 3 design.

Argument 3: Market size justifies persistence. Oral GLP-1 has a multi-billion-dollar addressable market. Even a third-place position could be commercially meaningful.

Argument 4: Competitive dynamics change. Orforglipron could encounter its own development problems. Walking away pre-emptively reduces optionality.

The counterargument: Pfizer's own data was the ceiling. The GI signal was structural, not refinable through trial design. The opportunity cost of phase 3 was a billion dollars or more. The decision to redirect was sound.

Decision framework

If you were waiting for danuglipron: the drug is not coming. Orforglipron is the next likely oral GLP-1 for obesity.

If you want an oral GLP-1 option now: Rybelsus is approved for type 2 diabetes. Off-label use for weight loss occurs but is not FDA-approved.

If you encounter "danuglipron" sold online: the product is not the clinical compound. The molecule is not commercially manufactured.

If you are following Pfizer for investment or analysis: the company's obesity position is a strategic concern that has not been addressed with a comparable-scale replacement asset.

FAQ

When was danuglipron discontinued? Twice-daily formulation: December 1, 2023. Once-daily modified-release: paused during 2024-2025.

Why didn't reformulation save it? Modified-release pharmacokinetics produced smoother exposure but modest tolerability gains. Combined with competitive disadvantage, the math did not work.

Did the FDA reject danuglipron? No. The drug was never submitted for FDA review. The discontinuation was a sponsor decision before approval was sought.

Was danuglipron unsafe? Not in the sense of dangerous side effects. Tolerability was the issue (mostly transient GI), not catastrophic safety.

Are the patients in the danuglipron trials okay? No reports of lasting harm. GI adverse events resolved with discontinuation.

Why didn't Pfizer license danuglipron to another company? No partner publicly bid on the asset. The competitive landscape made it commercially undesirable.

Is danuglipron in academic research? The molecule continues to appear in scientific literature as a comparator and as a case study in GLP-1 pharmacology.

Could the same molecule work as an injection? Theoretically possible, but small molecules are usually designed for oral administration. Pfizer did not pursue injectable danuglipron.

Did the discontinuation hurt Pfizer's stock? Yes, modestly. The announcement contributed to broader pessimism about Pfizer's growth pipeline.

Will another company pick up the program? No public disclosure of any acquirer.

What does this mean for me as a patient? Practically, nothing directly. Existing approved obesity drugs remain the relevant options. The oral GLP-1 field has one less candidate in development.

Related guides

• What Is Danuglipron? The Rise and Fall of Pfizer's Oral GLP-1
• What Is Orforglipron? Lilly's Oral GLP-1 Pill, Explained
• Oral vs Injectable GLP-1: Why a Pill Took So Long to Make

Sources

1. Pfizer Inc. Press Release: Pfizer Provides Update on Phase 2 Studies of Lead Oral GLP-1 Receptor Agonist, Danuglipron. December 1, 2023.
2. Pfizer R&D Day Materials and Investor Disclosures. 2023-2024.
3. Saxena AR et al. Danuglipron phase 2b results in type 2 diabetes. JAMA Network Open or comparable. 2023.
4. Wharton S et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (phase 2). New England Journal of Medicine. 2023.
5. Knop FK et al. Oral semaglutide 50 mg in overweight or obesity (OASIS 1). Lancet. 2023.
6. Bays HE et al. The Pharmacotherapy of Obesity. Endocrine Reviews. 2023.
7. STAT News coverage of Pfizer obesity portfolio strategy. 2023-2024.
8. Reuters analysis of obesity drug pipeline competition. 2024.
9. Bloomberg pharmaceutical industry coverage. 2023-2024.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed prescribers and pharmacies. We do not manufacture or supply danuglipron, which is not commercially available. Clinical decisions about available alternatives belong to your prescriber.

Discontinued Drug Notice. Danuglipron is a discontinued investigational compound. It is not FDA-approved, never reached commercial sale, and has no clear path to future approval as of May 2026. Online vendors using the name "danuglipron" are not selling the Pfizer clinical product.

Results Disclaimer. Phase 2 efficacy and tolerability data referenced in this article are from controlled trial populations. The drug's discontinuation prevented accumulation of phase 3 or real-world data. Tolerability signals discussed are interpretive based on disclosed information.

Trademark Notice. Danuglipron is the generic name of the discontinued Pfizer development compound. Rybelsus, Wegovy, and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Pfizer is a trademark of Pfizer Inc. FormBlends is not affiliated with these companies.